Atrial Septal Defect Closure in India and UAE | Complete Patient Guide

• IDEAL CANDIDATES FOR ASD CLOSURE:

• Patients with echocardiographically confirmed ASD with Qp:Qs ≥ 1.5:1 and right ventricular volume overload (Class I indication)

• Patients with any-sized ASD and a history of cryptogenic stroke or TIA attributable to paradoxical embolism (Class I, device closure preferred)

• Symptomatic patients with exertional dyspnoea, reduced exercise tolerance, or palpitations attributable to right heart volume overload

• Asymptomatic patients with progressive right atrial or right ventricular enlargement on serial imaging

• Patients with newly diagnosed atrial arrhythmias (atrial fibrillation/flutter) in the setting of ASD

• Age range: neonates through elderly adults (no absolute upper age limit; risk-benefit assessment required in patients >60 years)

• REQUIRED DIAGNOSTIC WORK-UP:

• Transthoracic Echocardiography (TTE): baseline right heart dimensions, shunt direction, estimated RVSP

• Transoesophageal Echocardiography (TOE) or 3D Intracardiac Echocardiography (ICE): precise defect diameter, rim assessment (aortic, posterior, inferior, superior vena caval, and atrioventricular rims), and device sizing

• Cardiac MRI (CMR): quantitative Qp:Qs measurement, RV volumes and function, anomalous pulmonary vein mapping (especially for sinus venosus defects)

• Right Heart Catheterisation: mandatory when pulmonary artery systolic pressure >40 mmHg on echo to measure pulmonary vascular resistance (PVR) and vasoreactivity testing

• ECG: right axis deviation, right bundle branch block pattern (rSR'), P-pulmonale

• Chest X-ray: cardiomegaly, pulmonary plethora

• Full blood count, coagulation profile, renal and hepatic function, HbA1c (if diabetic)

• CT Pulmonary Angiography or Coronary CT Angiography: as indicated in adults ≥40 years or when anatomy is complex

• CONTRAINDICATIONS:

• Severe irreversible pulmonary arterial hypertension (Eisenmenger syndrome): PVR >8 Wood Units unresponsive to vasodilator testing (absolute contraindication to closure)

• ASDs not amenable to device closure with deficient or absent rims (<5 mm aortic rim may still be acceptable; absent posterior/inferior rim is a contraindication to percutaneous closure)

• Active intracardiac infection or endocarditis

• Severe left ventricular diastolic dysfunction (LV EDP >15 mmHg post-balloon occlusion test) — device closure may precipitate acute pulmonary oedema

• Uncorrected coagulopathy or active systemic bleeding

• Body weight <8 kg for most commercially available ASD occluder devices (relative contraindication; surgical repair preferred)

TRANSCATHETER (PERCUTANEOUS) ASD DEVICE CLOSURE — PREFERRED FOR ELIGIBLE SECUNDUM ASDs:

This is the gold standard for haemodynamically significant ostium secundum ASDs with adequate septal rims and a maximum stretched diameter ≤38 mm (device-specific). Performed in a cardiac catheterisation laboratory under general anaesthesia (children) or conscious sedation (cooperative adults), the procedure uses a transfemoral venous approach. A sizing balloon catheter is advanced across the defect to measure the stretched diameter. The chosen occluder device—most commonly the Amplatzer Septal Occluder (Abbott) or Gore Cardioform ASD Occluder—is delivered via a long sheath and deployed under real-time fluoroscopic guidance combined with 3D transoesophageal echocardiography (TOE) or intracardiac echocardiography (ICE). ICE guidance eliminates the need for general anaesthesia in adults, allowing same-day or next-morning discharge in selected cases. The nitinol double-disc design of the Amplatzer device self-centres across the defect; complete endothelialisation occurs over 3–6 months, after which dual antiplatelet therapy (aspirin + clopidogrel for 6 months, then aspirin monotherapy for 6 months) is typically discontinued. Procedural success rate: >97%.

OPEN SURGICAL ASD REPAIR — INDICATED FOR NON-SECUNDUM DEFECTS OR DEVICE-INELIGIBLE PATIENTS:

Performed on cardiopulmonary bypass (CPB) with cardioplegic cardiac arrest. For ostium primum ASDs, repair includes patch closure of the interatrial communication and reconstruction of the cleft mitral valve (if present). Sinus venosus ASDs require complex baffle repair (Warden procedure or superior vena cava-right pulmonary artery baffle) to redirect anomalous pulmonary veins into the left atrium. Pericardial patch (autologous, glutaraldehyde-fixed) or synthetic Gore-Tex/Dacron patch is used for large defects. Standard median sternotomy provides excellent exposure; perioperative transesophageal echo confirms complete closure and valvular competence prior to decannulation.

MINIMALLY INVASIVE SURGICAL APPROACHES (available at select centres in India and the UAE):

• Right Mini-Thoracotomy (Port-Access Surgery): 4–5 cm right lateral chest incision with femoral cardiopulmonary bypass, videoscopic assistance, and specialised instruments. Offers superior cosmesis, avoids sternotomy, reduces blood loss by ~30%, and shortens ICU stay to 12–24 hours. Available at leading centres such as Narayana Health (Bengaluru), Apollo Hospitals, and Cleveland Clinic Abu Dhabi.

• Robotic-Assisted ASD Repair (da Vinci Surgical System): Fully endoscopic repair via 3–4 keyhole ports (8 mm). Achieves equivalent haemodynamic outcomes to open repair with minimal scarring, faster return to activity, and reduced post-operative pain. Increasingly available at premium centres in India (Fortis, Manipal) and select UAE hospitals.

• Thoracoscopic/Video-Assisted Repair: Hybrid approach used for moderate-complexity cases not suitable for full robotic repair.

ADJUNCT AND EMERGING TECHNOLOGIES:

• 3D Printing for Pre-Procedural Planning: Patient-specific 3D-printed cardiac models used for device sizing and surgical simulation in complex or large defects.

• Real-Time 3D Intracardiac Echocardiography (ICE): Next-generation ICE catheters (e.g., ViewFlex Xtra ICE Catheter, Abbott) provide superior imaging without TOE and without general anaesthesia.

• Pulmonary Vasodilator Therapy Bridge: In borderline PAH cases (PVR 5–8 Wood Units), a 3–6 month trial of phosphodiesterase-5 inhibitors (sildenafil, tadalafil) or endothelin receptor antagonists (bosentan, ambrisentan) may reduce PVR sufficiently to permit safe closure (fenestrated device or staged closure considered).

PHASE 1 — PRE-ARRIVAL & REMOTE CONSULTATION (Weeks 1–2 before travel): Patient submits medical records, echocardiogram reports, and cardiac MRI (if available) to GAF Healthcare's medical coordination team. Records are reviewed by a shortlisted congenital cardiologist within 48–72 hours. A detailed treatment plan—including recommended approach (device vs. surgical), estimated costs, and hospital selection—is provided. GAF Healthcare initiates the Indian e-Medical visa application (processed in 3–5 business days) or UAE visit/medical visa coordination. Pre-travel checklist issued: medications to continue/withhold (e.g., anticoagulants, antiplatelet agents), dietary guidelines, and NPO (nil-per-os) instructions for the procedure date.

PHASE 2 — ARRIVAL & IN-HOSPITAL ASSESSMENT (Days 1–2): GAF Healthcare-arranged airport transfer to hospital or partner accommodation. On Day 1: outpatient consultation with the treating cardiologist, repeat TTE, 12-lead ECG, full blood panel, coagulation screen, and chest X-ray. For device closure candidates: TOE or ICE under light sedation to finalise device sizing. For surgical candidates: anaesthesia pre-assessment, cardiac MRI or CT if not recently performed, pulmonary function tests. Informed consent obtained in the patient's preferred language (GAF translators available). Anaemia, hypertension, or metabolic derangements corrected prior to procedure.

PHASE 3 — THE PROCEDURE (Day 2–3): Transcatheter Device Closure: Patient is taken to the cath lab; the procedure takes approximately 45–90 minutes. Femoral venous access obtained, transseptal approach if needed, device deployed under fluoroscopic + ICE/TOE guidance. Post-deployment echo confirms device position, absence of residual shunt, and mitral/tricuspid valve competence. Patient moved to a monitored step-down unit. Open/Minimally Invasive Surgical Repair: General anaesthesia induced; procedure duration 2–4 hours (sternotomy) or 3–5 hours (robotic/mini-thoracotomy). CPB initiated; defect repaired under direct vision with patch material; TOE confirms complete closure before weaning from bypass. Patient transferred to cardiac ICU.

PHASE 4 — IMMEDIATE POST-PROCEDURE RECOVERY (Days 3–7): Transcatheter patients: Monitored for 4–6 hours post-procedure; ECG and echo performed; aspirin 75–100 mg + clopidogrel 75 mg initiated; discharged Day 2–3 post-procedure if stable. Device position confirmed on chest X-ray and TTE before discharge. Surgical patients: ICU stay 24–48 hours; chest drain management; IV analgesia transitioned to oral; early ambulation on Day 2; transition to telemetry ward Day 3; discharge Day 5–7 with wound care instructions, aspirin, and beta-blocker if indicated.

PHASE 5 — POST-DISCHARGE RECOVERY IN COUNTRY (Days 7–21): GAF Healthcare arranges follow-up echocardiogram and clinical review at Day 7–10 post-procedure. For device closure patients: assessment of device position, ruling out pericardial effusion, and confirming absence of residual shunt (small residual shunts <1 mm resolve spontaneously in 90% of cases within 6 months). For surgical patients: wound inspection, staple/suture removal (Day 10–14), spirometry, and graduated ambulation programme. Strenuous activity restricted for 6–8 weeks post-surgery (2–4 weeks post-device closure).

PHASE 6 — FIT-TO-FLY CLEARANCE & DEPARTURE: Transcatheter patients cleared to fly at 1–2 weeks post-procedure (subject to individual cardiologist assessment). Surgical patients cleared at 2–3 weeks post-procedure. GAF Healthcare provides a detailed discharge summary in English (and translated copy if requested), antiplatelet/medication prescription for 6–12 months, and a remote follow-up protocol for the patient's home cardiologist. Compression stockings recommended for long-haul flights. Emergency contact available 24/7 during travel window.